Akebia Therapeutics (AKBA) Given Coverage Optimism Score of 0.11

Press coverage about Akebia Therapeutics (NASDAQ:AKBA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.7906255281648 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of Akebia Therapeutics (NASDAQ AKBA) opened at $14.98 on Wednesday. Akebia Therapeutics has a 52-week low of $8.58 and a 52-week high of $20.25. The firm has a market capitalization of $741.18, a price-to-earnings ratio of -4.74 and a beta of 0.87.

Akebia Therapeutics (NASDAQ:AKBA) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%. The business had revenue of $41.28 million during the quarter, compared to the consensus estimate of $34.00 million. equities analysts expect that Akebia Therapeutics will post -2.25 EPS for the current fiscal year.

Several research firms have commented on AKBA. Mizuho began coverage on shares of Akebia Therapeutics in a research note on Wednesday, October 4th. They set a “buy” rating and a $24.00 price objective for the company. Zacks Investment Research lowered shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. ValuEngine lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price objective on shares of Akebia Therapeutics in a research note on Wednesday, November 15th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $17.00 price objective on shares of Akebia Therapeutics in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. Akebia Therapeutics currently has an average rating of “Buy” and a consensus price target of $22.20.

ILLEGAL ACTIVITY NOTICE: “Akebia Therapeutics (AKBA) Given Coverage Optimism Score of 0.11” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://stocknewstimes.com/2018/01/17/akebia-therapeutics-akba-given-coverage-optimism-score-of-0-11.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Insider Buying and Selling by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply